These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29066413)

  • 1. Effects of incretin-based therapies on renal function.
    Tsimihodimos V; Elisaf M
    Eur J Pharmacol; 2018 Jan; 818():103-109. PubMed ID: 29066413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiology and pathophysiology of incretins in the kidney.
    von Websky K; Reichetzeder C; Hocher B
    Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):54-60. PubMed ID: 24257158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the Way to Someone's Heart Through Their Stomach? The Cardiorenal Paradox of Incretin-Based Hypoglycemic Drugs in Heart Failure.
    Packer M
    Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29021350
    [No Abstract]   [Full Text] [Related]  

  • 4. The potential for renoprotection with incretin-based drugs.
    Tanaka T; Higashijima Y; Wada T; Nangaku M
    Kidney Int; 2014 Oct; 86(4):701-11. PubMed ID: 25007170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats.
    Zhou X; Huang CH; Lao J; Pocai A; Forrest G; Price O; Roy S; Kelley DE; Sullivan KA; Forrest MJ
    Cardiovasc Diabetol; 2015 Mar; 14():29. PubMed ID: 25888997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence.
    Kawanami D; Matoba K; Sango K; Utsunomiya K
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27483245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updates of incretin-related drugs for the treatment of type 2 diabetes.
    Araki H; Matsumura T; Furukawa N; Araki E
    J Diabetes Investig; 2023 Feb; 14(2):189-192. PubMed ID: 36373430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip.
    Luconi M; Cantini G; Ceriello A; Mannucci E
    Int J Cardiol; 2017 Aug; 241():302-310. PubMed ID: 28285800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renoprotection in diabetic kidney disease: can incretin-based therapies deliver?
    van Baar MJB; van Raalte DH
    Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):103-111. PubMed ID: 31714285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal Effects of Incretin-Based Diabetes Therapies: Pre-clinical Predictions and Clinical Trial Outcomes.
    Thomson SC; Vallon V
    Curr Diab Rep; 2018 Apr; 18(5):28. PubMed ID: 29654381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Diabetes Medications Targeting the Incretin System on the Kidney.
    MacIsaac RJ; Thomas MC
    Clin J Am Soc Nephrol; 2018 Feb; 13(2):321-323. PubMed ID: 29321176
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors.
    Sachinidis A; Nikolic D; Stoian AP; Papanas N; Tarar O; Rizvi AA; Rizzo M
    Metabolism; 2020 Oct; 111():154343. PubMed ID: 32810485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incretin-based therapies and cardiovascular risk.
    Mannucci E; Dicembrini I
    Curr Med Res Opin; 2012 May; 28(5):715-21. PubMed ID: 22439700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New prospects for incretin-related drugs in the treatment of type 2 diabetes.
    Kimura T; Kaku K
    J Diabetes Investig; 2021 Jul; 12(7):1141-1143. PubMed ID: 33151639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incretins in the Therapy of Diabetic Kidney Disease.
    Przezak A; Bielka W; Pawlik A
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cardiovascular Effects of Incretin-Based Therapies and Their Therapeutic Potential].
    Tyurenkov IN; Bakulin DA; Kurkin DV; Volotova EV
    Vestn Ross Akad Med Nauk; 2017; 72(1):66-75. PubMed ID: 29308856
    [No Abstract]   [Full Text] [Related]  

  • 17. Incretins and Lipid Metabolism.
    Tsimihodimos V; Elisaf M
    Curr Med Chem; 2018; 25(18):2133-2139. PubMed ID: 28413961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretins: Beyond type 2 diabetes.
    Dandona P; Ghanim H; Chaudhuri A
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():59-67. PubMed ID: 29364583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antioxidative Potentials of Incretin-Based Medications: A Review of Molecular Mechanisms.
    Yaribeygi H; Maleki M; Sathyapalan T; Jamialahmadi T; Sahebkar A
    Oxid Med Cell Longev; 2021; 2021():9959320. PubMed ID: 34007411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin-based therapies and renin-angiotensin system: Looking for new therapeutic potentials in the diabetic milieu.
    Yaribeygi H; Maleki M; Sathyapalan T; Jamialahmadi T; Sahebkar A
    Life Sci; 2020 Sep; 256():117916. PubMed ID: 32534034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.